Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Adams, S. Loi, D. Toppmeyer, D. Cescon, M. Laurentiis, R. Nanda, E. Winer, H. Mukai, K. Tamura, A. Armstrong, M. Liu, H. Iwata, L. Ryvo, P. Wimberger, H. Rugo, A. Tan, C. D'Aquanno, Y. Ding, V. Karantza, P. Schmid (2018)
Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)Cancer Research, 78
S. Loi, A. Giobbie-Hurder, A. Gombos, T. Bachelot, R. Hui, G. Curigliano, M. Campone, L. Biganzoli, H. Bonnefoi, G. Jerusalem, R. Bartsch, M. Rabaglio-Poretti, R. Kammler, R. Maibach, M. Smyth, A. Leo, M. Colleoni, G. Viale, M. Regan, F. André (2017)
Phase Ib/II study evaluating safety and efficacy of Pembrolizumab and Trastuzumab in patients with Trastuzumab-resistant HER2-positive advanced breast cancer : results from the PANACEA study (IBCSG 45-13/BIG 4-13/KEYNOTE-014)
P. Schmid, C. Cruz, F. Braiteh, J. Eder, S. Tolaney, I. Kuter, R. Nanda, C. Chung, P. Cassier, J. Delord, M. Gordon, Yijin Li, Bo Liu, C. O'Hear, M. Fassò, L. Molinero, L. Emens (2017)
Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analysesCancer Research, 77
S. Tolaney, C. Savulsky, G. Aktan, D. Xing, A. Almonte, V. Karantza, S. Diab (2017)
Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancerEuropean Journal of Cancer, 72
C. Adem, Cheryl Soderberg, J. Cunningham, C. Reynolds, T. Sebo, S. Thibodeau, L. Hartmann, Robert Jenkins (2003)
Microsatellite instability in hereditary and sporadic breast cancersInternational Journal of Cancer, 107
P. Schmid, Yeon-Hee Park, E. Muñoz-Couselo, Sung-Bae Kim, J. Sohn, S. Im, E. Holgado, Yang Wang, T. Dang, G. Aktan, J. Cortés (2017)
Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.Journal of Clinical Oncology, 35
R. Herbst, P. Baas, Dong-Wan Kim, E. Felip, J. Pérez-Gracia, Ji-Youn Han, J. Molina, Joo‐Hang Kim, C. Arvis, M. Ahn, M. Majem, M. Fidler, G. Castro, M. Garrido, G. Lubiniecki, Shentu Yue, E. Im, M. Dolled-Filhart, E. Garon (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 387
Yan Zeng, Cheng-long Wang, Jie Xian, Q. Ye, Xue Qin, Yiwen Tan, Youde Cao (2019)
Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancerOncoTargets and therapy, 12
C. Lord, A. Ashworth (2017)
PARP inhibitors: Synthetic lethality in the clinicScience, 355
Daniel Chen, I. Mellman (2013)
Oncology meets immunology: the cancer-immunity cycle.Immunity, 39 1
M. Dieci, M. Mathieu, V. Guarneri, P. Conte, S. Delaloge, F. André, F. André, A. Goubar (2015)
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.Annals of oncology : official journal of the European Society for Medical Oncology, 26 8
S. Tolaney, K. Kalinsky, V. Kaklamani, C. Savulsky, M. Olivo, G. Aktan, P. Kaufman, D. Xing, A. Almonte, S. Misir, V. Karantza, S. Diab (2017)
Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancerCancer Research, 78
S. Loi, D. Drubay, S. Adams, P. Francis, H. Joensuu, M. Dieci, S. Badve, S. Demaria, R. Gray, M. Piccart, P-L Kellokumpa-Lehtinen, F. André, I. Dufaure-Garé, C. Denkert, R. Salgado, S. Michiels (2016)
Abstract S1-03: Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapyCancer Research, 76
S. Middha, Liying Zhang, K. Nafa, G. Jayakumaran, D. Wong, H. Kim, Justyna Sadowska, M. Berger, D. DeLair, J. Shia, Z. Stadler, D. Klimstra, M. Ladanyi, A. Zehir, J. Hechtman (2017)
Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data.JCO precision oncology, 2017
L. Alexandrov, S. Nik-Zainal, D. Wedge, S. Aparicio, S. Behjati, A. Biankin, G. Bignell, N. Bolli, Å. Borg, A. Børresen-Dale, S. Boyault, B. Burkhardt, A. Butler, C. Caldas, H. Davies, C. Desmedt, R. Eils, J. Eyfjörd, J. Foekens, M. Greaves, F. Hosoda, B. Hutter, Tomislav Ilicic, S. Imbeaud, Marcin Imielinsk, N. Jäger, David Jones, David Jones, S. Knappskog, M. Kool, S. Lakhani, C. López-Otín, Sancha Martin, N. Munshi, Hiromi Nakamura, P. Northcott, M. Pajic, E. Papaemmanuil, A. Paradiso, J. Pearson, X. Puente, K. Raine, Manasa Ramakrishna, A. Richardson, J. Richter, P. Rosenstiel, M. Schlesner, T. Schumacher, P. Span, J. Teague, Y. Totoki, A. Tutt, R. Valdés-Mas, Marit Buuren, L. Veer, A. Vincent-Salomon, N. Waddell, L. Yates, J. Zucman‐Rossi, P. Futreal, U. McDermott, P. Lichter, M. Meyerson, S. Grimmond, R. Siebert, E. Campo, T. Shibata, S. Pfister, P. Campbell, M. Stratton (2013)
Signatures of mutational processes in human cancerNature, 500
C. Chambers, M. Kuhns, J. Egen, J. Allison (2001)
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.Annual review of immunology, 19
R. Nanda, L. Chow, C. Dees, R. Berger, Shilpa Gupta, R. Geva, L. Pusztai, K. Pathiraja, G. Aktan, Jonathan Cheng, V. Karantza, L. Buisseret (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 21
S. Adams, R. Gray, S. Demaria, L. Goldstein, E. Perez, L. Shulman, S. Martino, Molin Wang, V. Jones, T. Saphner, A. Wolff, W. Wood, N. Davidson, G. Sledge, J. Sparano, S. Badve (2014)
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 27
R. Siegel, K. Miller, A. Jemal (2017)
Cancer statistics, 2017CA: A Cancer Journal for Clinicians, 67
S. Loi, S. Adams, P. Schmid, J. Cortés, D. Cescon, E. Winer, D. Toppmeyer, H. Rugo, M. Laurentiis, R. Nanda, H. Iwata, A. Awada, A. Tan, A. Wang, G. Aktan, V. Karantza, R. Salgado (2017)
LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086Annals of Oncology, 28
R. Anbazhagan, H. Fujii, E. Gabrielson (1999)
Microsatellite instability is uncommon in breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 5 4
S. Domchek, S. Postel-Vinay, Y. Bang, Yong Park, J. Alexandre, J. Delord, A. Italiano, B. You, S. Bastian, M. Krebs, Ding Wang, S. Waqar, H. Angell, M. Learoyd, S. Chang, C. Gresty, P. Herbolsheimer, B. Kaufman (2018)
Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)Cancer Research, 78
R. Nanda, Minetta Liu, C. Yau, S. Asare, N. Hylton, Laura Veer, J. Perlmutter, A. Wallace, A. Chien, A. Forero-Torres, E. Ellis, Heather Han, Amy Clark, K. Albain, Judy Boughey, A. Elias, D. Berry, D. Yee, A. DeMichele, L. Esserman (2017)
Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.Journal of Clinical Oncology, 35
S. Loi, A. Giobbe-Hurder, A. Gombos, T. Bachelot, R. Hui, G. Curigliano, M. Campone, L. Biganzoli, H. Bonnefoi, G. Jerusalem, R. Bartsch, M. Rabaglio-Poretti, R. Kammler, R. Maibach, M. Smyth, A. Leo, M. Colleoni, G. Viale, M. Regan, F. André (2018)
Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) studyCancer Research, 78
Mark Robson, Elżbieta Senkus, Binghe Xu, S. Domchek, N. Masuda, S. Delaloge, Nadine Tung, Anne Armstrong, Wenting Wu, Carsten Goessl, S. Runswick, Pierfranco Conte (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.The New England journal of medicine, 377 17
P. Savas, R. Salgado, C. Denkert, C. Sotiriou, P. Darcy, M. Smyth, S. Loi (2016)
Clinical relevance of host immunity in breast cancer: from TILs to the clinicNature Reviews Clinical Oncology, 13
C. Denkert, G. Minckwitz, S. Darb-Esfahani, B. Lederer, B. Heppner, K. Weber, J. Budczies, J. Huober, F. Klauschen, J. Furlanetto, W. Schmitt, J. Blohmer, T. Karn, B. Pfitzner, S. Kümmel, K. Engels, A. Schneeweiss, A. Hartmann, A. Noske, P. Fasching, C. Jackisch, M. Mackelenbergh, P. Sinn, C. Schem, C. Hanusch, M. Untch, S. Loibl (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.The Lancet. Oncology, 19 1
J. Litton, H. Rugo, J. Ettl, S. Hurvitz, A. Gonçalves, K. Lee, L. Fehrenbacher, R. Yerushalmi, L. Mina, M. Martín, H. Roché, Y. Im, R. Quek, I. Tudor, A. Hannah, W. Eiermann, J. Blum (2018)
Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutationCancer Research, 78
L. Dirix, I. Takács, P. Nikolinakos, G. Jerusalem, H. Arkenau, E. Hamilton, A. Heydebreck, H. Grote, K. Chin, M. Lippman (2016)
Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trialCancer Research, 76
S. Loi, S. Loi, S. Michiels, S. Michiels, R. Salgado, N. Sirtaine, V. Jose, D. Fumagalli, P. Kellokumpu-Lehtinen, P. Bono, V. Kataja, C. Desmedt, M. Piccart, S. Loibl, C. Denkert, M. Smyth, H. Joensuu, C. Sotiriou (2014)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.Annals of oncology : official journal of the European Society for Medical Oncology, 25 8
T. Toyama, H. Iwase, H. Yamashita, H. Iwata, T. Yamashita, Kazuko Ito, Y. Hara, M. Suchi, Taiji Kato, Takaaki Nakamura, S. Kobayashi (1996)
Microsatellite instability in sporadic human breast cancersInternational Journal of Cancer, 68
A. Ribas, I. Puzanov, R. Dummer, D. Schadendorf, O. Hamid, C. Robert, F. Hodi, J. Schachter, A. Pavlick, Karl Lewis, L. Cranmer, Christian Blank, S. O'Day, P. Ascierto, April Salama, K. Margolin, C. Loquai, Thomas Eigentler, T. Gangadhar, M. Carlino, S. Agarwala, S. Moschos, J. Sosman, S. Goldinger, R. Shapira-Frommer, R. Gonzalez, J. Kirkwood, J. Wolchok, A. Eggermont, Xiaoyun Li, W. Zhou, Adriane Zernhelt, Joy Lis, S. Ebbinghaus, S. Kang, A. Daud (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.The Lancet. Oncology, 16 8
D. Pardoll (2012)
The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 12
S. Luen, R. Salgado, S. Fox, P. Savas, J. Eng-Wong, E. Clark, A. Kiermaier, S. Swain, J. Baselga, S. Michiels, S. Loi (2017)
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.The Lancet. Oncology, 18 1
S. Adams, J. Diamond, E. Hamilton, P. Pohlmann, S. Tolaney, L. Molinero, Xian He, D. Waterkamp, R. Funke, J. Powderly (2016)
Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).Journal of Clinical Oncology, 34
C. Langer, S. Gadgeel, H. Borghaei, V. Papadimitrakopoulou, A. Patnaik, S. Powell, R. Gentzler, R. Martins, J. Stevenson, S. Jalal, A. Panwalkar, J. Yang, M. Gubens, L. Sequist, M. Awad, J. Fiore, Y. Ge, H. Raftopoulos, L. Gandhi (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.The Lancet. Oncology, 17 11
E. Vilar, S. Gruber (2010)
Microsatellite instability in colorectal cancer—the stable evidenceNature Reviews Clinical Oncology, 7
H. Rugo, J. Delord, S. Im, P. Ott, S. Piha-Paul, P. Bedard, J. Sachdev, C. Tourneau, E. Brummelen, A. Varga, S. Saraf, Dina Pietrangelo, V. Karantza, A. Tan (2016)
Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028Cancer Research, 76
S. Adams, P. Schmid, H. Rugo, E. Winer, D. Loirat, A. Awada, D. Cescon, H. Iwata, M. Campone, R. Nanda, R. Hui, G. Curigliano, D. Toppmeyer, J. O’Shaughnessy, S. Loi, S. Paluch-Shimon, D. Card, Jing Zhao, V. Karantza, J. Cortés (2017)
Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.Journal of Clinical Oncology, 35
C. Denkert, S. Loibl, A. Noske, M. Roller, B. Müller, M. Komor, J. Budczies, S. Darb-Esfahani, R. Kronenwett, C. Hanusch, C. Törne, W. Weichert, K. Engels, C. Solbach, I. Schrader, M. Dietel, G. Minckwitz (2010)
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 1
(2017)
Atezolizumab in metastatic triple-negative breast cancer: long-term clinical outcomes and biomarker analyses. American Association for Cancer Research (AACR Annual Meeting) 2017; Abstract 2986
T. Schumacher, R. Schreiber (2015)
Neoantigens in cancer immunotherapyScience, 348
Russell Bonneville, M. Krook, Esko Kautto, Jharna Miya, M. Wing, Hui-Zi Chen, Julie Reeser, Lianbo Yu, S. Roychowdhury (2017)
Landscape of Microsatellite Instability Across 39 Cancer Types.JCO precision oncology, 2017
C. DeSantis, Jiemin Ma, Ann Sauer, L. Newman, A. Jemal (2017)
Breast cancer statistics, 2017, racial disparity in mortality by stateCA: A Cancer Journal for Clinicians, 67
Purpose of Review The treatment landscape for many cancers has dramatically changed with the development of checkpoint inhibitors. This article will review the literature concerning the use of checkpoint inhibitors in breast cancer. Recent Findings The histological subtype of BC with the strongest signal of efficacy has been triple-negative breast cancer (TNBC). Early trials of single-agent checkpoint inhibitors did not demonstrate a uniformly positive signal. Clinical studies suggest response rates between 5 and 10% in pretreated patients and roughly 20–25% for untreated advanced TNBC. However, in the small subset of patients who do respond, the response is often durable. More encouraging results have been reported with their use in combination with chemotherapy in the neoadjuvant setting. Larger phase III studies are underway to confirm these earlier findings. Summary An immune-directed therapeutic approach for the management of BC is underway, and it is likely that combination therapy will be required to achieve a level of efficacy worthy of use in the BC treatment paradigm. These agents are not without both economic and clinical toxicity; therefore, it is imperative that we identify patients most likely to benefit from these therapies through well-designed biologically plausible clinical studies and by evaluating novel combinatorial
Current Oncology Reports – Springer Journals
Published: Apr 30, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.